Prelude Therapeutics (PRLD) Cash & Current Investments (2019 - 2026)

Prelude Therapeutics has reported Cash & Current Investments for 8 years, with the latest figure at $144.6 million in Q1 2026.

• Quarterly Cash & Current Investments rose 40.23% year-over-year to $144.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $144.6 million (up 40.23% YoY) and the FY2025 annual result came in at $103.2 million, down 25.02% from the prior year.
• Cash & Current Investments advanced to $144.6 million in Q1 2026 per PRLD's latest filing, from $103.2 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $270.2 million in Q1 2022 and troughed at $55.0 million in Q3 2025.
• A 5-year average of $181.0 million and a median of $183.9 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2025 and 2026: Cash & Current Investments slumped 65.14% in 2025, then jumped 40.23% in 2026.
• Over 5 years, Cash & Current Investments stood at $205.8 million in 2022, then advanced by 15.17% to $237.0 million in 2023, then tumbled by 41.91% to $137.7 million in 2024, then retreated by 25.02% to $103.2 million in 2025, then soared by 40.1% to $144.6 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $144.6 million, $103.2 million, and $55.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.